Antimicrobial Agents and Chemotherapy · 2016 · 35 citations · 38 references
MedicineMicrobiologyPharmacologyAntimicrobial ResistanceChemotherapyMedical MicrobiologyAntibacterial ResistanceAntibiotic ResistanceChemotherapy ResistancePharmacokinetics Of AntimicrobialsPulmonary InfectionsHalf-life DeterminationIntracellular Infection TherapyMetabolic Half-lifeMycobacterial Disease
Mycobacterium avium-intracellulare complex (MAC) causes an intractable intracellular infection that presents as chronic pulmonary disease. Currently, therapy consists of ethambutol and macrolides and takes several years to complete. The neuroleptic phenothiazine thioridazine kills mycobacteria by inhibiting the electron transport chain. In several experiments with bacterial populations of up to 10(12) CFU/ml, we failed to isolate any bacteria resistant to 3 times the MIC of thioridazine, suggesting the absence of resistant mutants at bacterial burdens severalfold higher than those encountered in patients. In the hollow-fiber model of intracellular MAC (HFS-MAC), thioridazine achieved an extracellular half-life of 16.8 h and an intracellular half-life of 19.7 h. Thioridazine concentrations were >28,000-fold higher inside infected macrophages than in the HFS-MAC central compartment (equivalent to plasma). Thioridazine maximal kill was 5.20 ± 0.75 log10 CFU/ml on day 7 (r(2) = 0.96) and 7.19 ± 0.31 log10 CFU/ml on day 14 (r(2) = 0.99), the highest seen with any drug in the system. Dose fractionation studies revealed that thioridazine efficacy and acquired drug resistance were driven by the peak concentation-to-MIC ratio, with a 50% effective concentration (EC50) of 2.78 ± 0.44 for microbial killing. Acquired drug resistance was encountered by day 21 with suboptimal doses, demonstrating that fluctuating drug concentrations drive evolution faster than static concentrations in mutation frequency studies. However, the thioridazine EC50 changed 16.14-fold when the concentration of fetal bovine serum was changed from 0% to 50%, suggesting that intracellular potency could be heavily curtailed by protein binding. Efficacy in patients will depend on the balance between trapping of the drug in the pulmonary system and the massive intracellular concentrations versus very high protein binding of thioridazine.
38
Role of mutator alleles in adaptive evolution
François Taddéi, Miroslav Radman, John Maynard-Smith et al. · Nature · 1997 · 710 citations · Full text
Aurelia Schmalstieg, Shashikant Srivastava, Serkan Belkaya et al. · Antimicrobial Agents and Chemotherapy · 2012 · 198 citations · Full text